SUBUTEX

LOE Approaching

buprenorphine hydrochloride

NDASUBLINGUALTABLET
Approved
Oct 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5

Clinical Trials (5)

NCT01582347Phase 2Completed

Transfer of Subjects From Subutex/Suboxone to RBP-6300

Started Mar 2012
143 enrolled
Opioid Related Disorder
NCT00725608N/ACompleted

Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)

Started May 2008
339 enrolled
Opioid-Related DisordersOpiate DependenceDrug Abuse
NCT00605033Phase 4Completed

A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)

Started Mar 2008
241 enrolled
Opiate DependenceDrug Dependence
NCT00684073Phase 4Completed

Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)

Started Jul 2007
60 enrolled
Opiate-related DisordersOpiate DependenceDrug Abuse
NCT00723697N/ACompleted

Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)

Started May 2007
1,307 enrolled
BuprenorphineNaloxoneOpiate-related Disorders+2 more
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.